Stably Tethered Multivalent Protein Complexes via Dimerization Domains
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing multivalent structures with multiple specificities or functionalities face challenges such as high manufacturing costs, low expression yields, instability in serum, and heterogeneity, leading to undefined batch composition and reduced binding affinity due to steric factors or altered conformations.
Innovation Solution
The development of stably tethered structures, such as homodimers, homotetramers, and hybrid tetramers, using a dimerization and docking domain (DDD) sequence to link identical or distinct subunits, allowing for self-association and enhanced binding capabilities, which can be used to create multivalent proteins or protein-based constructs with improved stability and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant technologies are used to produce multivalent structures, then binding affinity and potency are improved, but manufacturing cost increases and expression yields decrease
Solution Approach 1:
The invention divides the multivalent structure into modular monomeric units that can be independently expressed and then assembled. Each monomer contains a specific functional domain (targeting or effector), allowing separate optimization of expression for each unit while maintaining the overall multivalent functionality through controlled assembly.
Solution Approach 2:
The invention creates universal monomeric building blocks with standardized interfaces (dimerization domains, linker regions) that can be combined in various configurations to produce different multivalent structures. This modular universality allows the same basic units to serve multiple functions and be assembled into diverse multivalent agents with different valencies and specificities.
2Adaptability or versatility
If chemical cross-linking methods are used to create multivalent structures, then multivalency is achieved, but product homogeneity decreases and manufacturing cost increases
Solution Approach 1:
The invention performs preliminary assembly of monomeric units into defined multivalent structures during the expression and purification process, before final formulation. The modular design with specific interaction domains (dimerization domains, linkers) enables controlled self-assembly into homogeneous multivalent products with defined stoichiometry, eliminating the need for post-purification cross-linking steps that would compromise homogeneity.
Solution Approach 2:
The monomeric units are designed with inherent self-assembly capabilities through built-in dimerization domains and complementary interaction interfaces. These units automatically organize into the desired multivalent configurations through their intrinsic biochemical properties, eliminating the need for external chemical cross-linking agents and enabling production of homogeneous products through self-organizing principles.
3Adaptability or versatility
If multivalent structures are produced with multiple product forms, then versatility is improved, but batch composition definition decreases
Solution Approach 1:
The invention incorporates specific local features (different dimerization domain variants, varied linker sequences, distinct interaction interfaces) at defined positions within the modular monomeric units. These localized variations enable the production of multivalent structures with multiple specificities and binding targets while maintaining overall batch homogeneity, as each variant is produced as a defined molecular entity rather than a mixture of undefined forms.
Data Source
AI summary
The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different. The disclosed methods and compositions provide a facile and general way to obtain homodimers, homotetramers and heterotetramers of virtually any functionality and/or binding specificity.